The Heart Institute of Good Samaritan Hospital, Los Angeles, CA, USA.
Am J Transplant. 2011 Nov;11(11):2297-301. doi: 10.1111/j.1600-6143.2011.03750.x. Epub 2011 Sep 19.
Over the last decade, many investigators have utilized bone marrow-derived cells for cell transplantation therapy in animal studies and in patients with acute myocardial infarction and chronic heart failure. In those experimental and clinical studies, various doses and types of bone marrow-derived cells have been transplanted to the injured myocardium using a variety of approaches, such as intracoronary infusion or catheter-based direct endomyocardial injection, and at different time points after successful coronary reperfusion. The reported treatment effects are variable, which may be related to differences in cell type and quantity of transplanted cells, timing and approach of cell transplantation and patient selection. In this review, we summarize and discuss the controversies and questions related to the clinical use of bone marrow-derived cells.
在过去的十年中，许多研究人员已经在动物研究和急性心肌梗死及慢性心力衰竭患者中利用骨髓来源的细胞进行细胞移植治疗。在这些实验和临床研究中，使用各种方法，如冠状动脉内输注或基于导管的直接心肌内注射，将各种剂量和类型的骨髓来源的细胞移植到损伤的心肌中，并在成功冠状动脉再灌注后的不同时间点进行。报告的治疗效果是可变的，这可能与移植细胞的细胞类型和数量、细胞移植的时间和方法以及患者选择的差异有关。在这篇综述中，我们总结并讨论了与骨髓来源的细胞临床应用相关的争议和问题。
